Editas Medicine has been granted a patent for genome editing systems allowing detection and measurement of on-target gene editing outcomes, including targeted integration. The method involves using donor templates with specific components. GlobalData’s report on Editas Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Editas Medicine, CRISPR genome editing was a key innovation area identified from patents. Editas Medicine's grant share as of January 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
Genome editing system for detecting and measuring gene editing outcomes
See Also:
A recently granted patent (Publication Number: US11866726B2) discloses an isolated nucleic acid designed for homologous recombination with a target nucleic acid containing a cleavage site. The nucleic acid includes specific sequences and structures, such as priming sites, homology arms, and stuffer sequences with defined characteristics. The composition further extends to a vector and a genome editing system incorporating the isolated nucleic acid, showcasing its potential applications in genetic engineering and biotechnology.
Moreover, the patent details a method for determining the outcome of a gene editing event at a cleavage site in a cell using an exogenous oligonucleotide donor template. This method involves forming breaks at the cleavage site, recombining the donor template with the target nucleic acid via homologous recombination, and amplifying the altered nucleic acid to assess the editing outcome. The method's specificity and precision are highlighted through various criteria, including the sequences of stuffer regions, homology arm lengths, and the nature of the cargo within the nucleic acid. Overall, the patent presents a comprehensive framework for genome editing and molecular biology research, offering a detailed guide for manipulating genetic material with enhanced accuracy and efficiency.
To know more about GlobalData’s detailed insights on Editas Medicine, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
